Read our latest updates & insights

On 14 July 2026, Formycon and OneSource Speciality Pharma announced that they have entered into a strategic manufacturing partnership for biosimilars.  OneSource is an Indian-based specialty pharma Contract Development & Manufacturing Organisation (CDMO) that provides e...

On 14 July 2026, ChosunBiz reported that Celltrion has voluntarily terminated the European Phase 3 trial of CT-P51, biosimilar to MSD’s Keytruda® (pembrolizumab), and has withdrawn its investigational new drug application.  The early termination of the trial in Europe is pa...

On 14 July 2026, Merck KGaA announced that Erbitux® (cetuximab) was approved by the European Commission for adults with BRAF V600E mutant metastatic colorectal cancer (mCRC) in combination with Pierre Fabre’s Braftovi® (encorafenib) and FOLFOX (fluorouracil, leucovori...

On 13 July 2026, Seoul Economic Daily reported that Samsung Bioepis has secured US formulary listings for Pyzchiva®/SB17, with two major pharmacy benefit managers (PBMs).

Pyzchiva® was listed as a preferred drug by CVS Caremark from 1 July 2026, following the inclusi...

On 13 July 2026, Shanghai Henlius Biotech announced that the first patient in the US has been dosed in its international multicentre Phase 1 clinical trial of HLX-15-SC (daratumumab and hyaluronidase-fihj), biosimilar to J&J’s Darzalex Faspro®, for the treatment o...

On 10 July 2026, the FDA announced that it approved each of MSD’s Keytruda® (pembrolizumab) and Keytruda Qlex™ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Astellas’ Padcev® (enfortumab vedotin), as neoadjuvant treatment followed by adjuvant treatment...

On 9 July 2026, Samsung Bioepis announced it signed a licence option agreement with Proteina, a Korean biotechnology company, to use the results of an R&D project aimed at developing AI-based antibody therpeutics.

The R&D project was launched in October 2025 ...

On 9 July 2026, PR Newswire reported that the FDA has approved Accord BioPharma’s Ennumo™, biosimilar to Amgen’s Neulasta® (pegfilgrastim), for all approved reference indications.

According to the announcement, Accord is now the only company in the US off...

On 9 July 2026, Teva and Polpharma Biologics announced that they entered into an exclusive licensing agreement for the commercialisation of intravenous and subcutaneous formulations of Polpharma Biologics’ PB018, biosimilar to Roche’s Ocrevus® (ocrelizumab).